Chugai Pharma Europe LRO 301 IL-6 Trial

Comprises records relating to the LRO 301 IL-6 trial, "a double blind, randomised parallel group, controlled dose ranging study of the safety, tolerability, pharmacokinetics, and efficacy of repeat doses of MRA given alone or in combination with MTX in patients with RA." The trial is also referred to as CHARISMA.

The aim of the trail was to determine the safety and effectiveness of MRA (humanised anti-human IL-6 receptor monoclonal antibody IgG1) when given alone or in combination with methotrexate. The trial was sponsored by Chugai Pharma Europe Ltd, conducted by the Kennedy Institute of Rheumatology with investigators were Ravinder Maini and Peter Taylor. The trial involved 359 patients from 57 recruiting sites across 14 European countries.

1996-2010

13 boxes

MRA is a drug developed under the name Tocilizumab, a biological therapy that worked to inhibit the overproduction of the IL-6 protein in the body. It can be taken as an alternative to other biological therapies such as anti-TNF or infliximab/Remicade.